# Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

> **NCT06899061** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 41 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** Saruparib
- **DRUG:** Digoxin
- **DRUG:** Furosemide
- **DRUG:** Metformin Hydrochloride
- **DRUG:** Rosuvastatin
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT06899061
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2026-02-03
- **Final completion:** 2026-04-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06899061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06899061, "Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06899061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*